Hillevax Inc

NASDAQ HLVX

Data sourced from

and

Download Data

Hillevax Inc Debt to Income Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending December 31, 2023: -180.88%

Hillevax Inc Debt to Income Ratio 1 year YoY Change (%) is -180.88% for the Trailing 12 Months (TTM) ending December 31, 2023. The debt to income ratio measures the level of debt relative to a company's net income. It is calculated by dividing total debt by net income. This ratio provides insights into the company's ability to generate sufficient income to cover its debt obligations. A higher ratio indicates a higher level of debt burden relative to the company's income. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Hillevax Inc Debt to Income Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was -0.44.

NASDAQ: HLVX

Hillevax Inc

CEO	Dr. Robert M. Hershberg M.D., Ph.D.
IPO Date	April 29, 2022
Location	United States
Headquarters	75 State Street, Boston, MA, United States, 02109
Employees	90
Sector	Healthcare
Industry	Biotechnology

Description

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Key trends